Showing 2401-2410 of 5771 results for "".
- Vital Tears Announces the Addition of Mobile Phlebotomy Serviceshttps://modernod.com/news/vital-tears-announces-the-addition-of-mobile-phlebotomy-services/2479692/Vital Tears announced the addition of mobile phlebotomy services to its system of providing autologous serum tears for dry eye therapy. By offering mobile phlebotomy services, patients can now have their blood drawn in the convenience of their own home or office. The addition of a mobile blood dr
- Horizon Pharma Announces Presentation of Results of 48 Week Off-Therapy Follow-Up to the Phase 2 Trial of Teprotumumab at AAOhttps://modernod.com/news/horizon-pharma-announces-presentation-of-results-of-48-week-off-therapy-follow-up-to-the-phase-2-trial-of-teprotumumab-at-aao/2479711/Horizon Pharma announced that more detailed results from the 48 week off-therapy follow-up to the phase 2 clinical trial of teprotumumab for people living with moderate-to-severe active thyroid eye disease (TED) were presented at the AAO annual meeting, Oct. 27–30, 2018, in Chicago. The data was
- Novaliq Announces Positive Topline Results for Its SEECASE Phase 2 Trial of NOV03 for the Treatment of Patients with Dry Eye Diseasehttps://modernod.com/news/novaliq-announces-positive-topline-results-for-its-seecase-phase-2-trial-of-nov03-for-the-treatment-of-patients-with-dry-eye-disease/2479732/Novaliq announces positive topline results for its SEECASE phase 2 clinical trial of NOV03 for the treatment of dry eye disease (DED) in more than 300 patients. NOV03 (100% perfluorohexyloctane) is a preservative-free ophthalmic solution and the first drug developed to treat evaporative DE
- Oyster Point Announces Positive Results From Two Phase 2b Clinical Trials of Investigational Treatments for Dry Eye Diseasehttps://modernod.com/news/oyster-point-announces-positive-results-from-two-phase-2b-clinical-trials-of-investigational-treatments-for-dry-eye-disease/2479733/Oyster Point Pharma announced results from the ONSET and RAINIER studies, two separate phase 2b clinical trials evaluating the company’s novel therapies for the treatment of dry eye disease (DED). Both studies, presented at the Ophthalmology Innovation Summit (OIS) meeting in Chicago, demonstrate
- CheckedUp Announces Expanding Reach in Vision Care and New Product Features at the Point of Carehttps://modernod.com/news/checkedup-announces-expanding-reach-in-vision-care-and-new-product-features-at-the-point-of-care/2479734/CheckedUp announced several new product features to optimize their health care decision technology. With more than 5,000 eye care professionals in the CheckedUp network, the technology empowers patients during their health care journey by engaging and educating them about their care, preventions,
- LumiThera and Optos Announce Collaboration to Commercialize the Valeda Light Delivery System for Treating Dry AMD in Europehttps://modernod.com/news/lumithera-and-optos-announce-collaboration-to-commercialize-the-valeda-light-delivery-system-for-treating-dry-amd-in-europe/2479740/LumiThera announced a distribution agreement with Optos to exclusively distribute the Valeda Light Delivery System for the treatment of dry age-related macular degeneration (AMD) in 12 European countries. The announcement follows the recent CE Mark certification for the European Union (EU) for th
- Alcon to Showcase Latest Innovations at American Academy of Ophthalmology 2018 Annual Meetinghttps://modernod.com/news/alcon-to-showcase-latest-innovations-at-american-academy-of-ophthalmology-2018-annual-meeting/2479748/Alcon will showcase several advancements in ophthalmology through a robust booth presence, a series of live demonstrations, and interactive symposia during the American Academy of Ophthalmology (AAO) 2018 annual meeting, taking place October 27-30 in Chicago, IL. “We are very excited to e
- Orasis Announces the Appointment of Jeffry Weinhuff as Chairman of the Board of Directorshttps://modernod.com/news/orasis-announces-the-appointment-of-jeffry-weinhuff-as-chairman-of-the-board-of-directors/2479771/Orasis Pharmaceuticals announced the appointment of Jeffry Weinhuff as chairman of the board of directors. As a managing partner of Visionary Ventures, Mr. Weinhuff joins the Orasis board of directors in conjunction with the recent Series B financing led by Visionary Ventures, a venture capital f
- Santen Announces Initiation of Phase 3 Clinical Program (SPECTRUM) Evaluating Glaucoma Treatment Omidenepag Isopropyl (DE-117)https://modernod.com/news/santen-announces-initiation-of-phase-3-clinical-development-program-spectrum-in-the-united-states-evaluating-omidenepag-isopropyl-de-117-for-the-treatment-of-glaucoma-or-ocular-hypertension/2479772/Santen announced the initiation of the pivotal phase 3 development program (SPECTRUM) in the United States, evaluating the investigational use of omidenepag isopropyl (DE-117), a selective agonist for the prostanoid receptor EP2, for the treatment of glaucoma or o
- Market Scope Announces Launch of New Website and Entry into Orthopedicshttps://modernod.com/news/market-scope-announces-launch-of-new-website-and-entry-into-orthopedics/2479792/Market Scope announced the launch of its new website and the firm’s entry into orthopedics, its second medical vertical. The new Market-Scope.com emphasizes user experience and features a customized and interactive dashboard where clients can access newsletters, survey results, and repor